Hematology
From the Journals
Genetic testing helps avoid false hemoglobinopathy diagnoses in newborns
“We now perform simultaneous protein-based and genetic testing as our standard clinical practice.”
Feature
U.S. cancer centers embroiled in Chinese research thefts
The U.S. Federal Bureau of Investigation has been ferreting out researchers it says have acted illegally.
Conference Coverage
BCL11A-directed gene therapy advances in sickle cell disease
ORLANDO – A phase 2/3 study is planned to assess the gene therapy in a larger group of patients with sickle cell disease.
Conference Coverage
Think twice: Choosing Wisely recommendations on testing to avoid in pediatric hematology
ORLANDO – The list, which was released by ASH and the American Society of Pediatric Hematology/Oncology, includes five unnecessary tests or...
Conference Coverage
NFIX could be a target for sickle cell therapy
ORLANDO – Preclinical research suggests it may be a fetal hemoglobin repressor.
Conference Coverage
Fragmentation of sickle cell disease care starts in young adulthood
ORLANDO – Imagine what that would be like to have a chronic, debilitating illness and to have to go to multiple different hospitals, during this...
News from the FDA/CDC
FDA approves Oxbryta for sickle cell disease treatment
The drug, which is approved for adults and children aged 12 years and older, improved hemoglobin in the HOPE trial.
News from the FDA/CDC
FDA approves treatment for sickle cell pain crises
Crizanlizumab-tmca (Adakveo) is approved for patients with sickle cell disease who are aged 16 years and older.
Latest News
Researchers seek a way to predict cognitive deficits in children treated for ALL
Researchers are investigating gene variants and biomarkers that might correlate with chemotherapy-induced cognitive deficits.
Conference Coverage
Fresh RBCs offer no benefit over older cells in pediatric ICU
SAN ANTONIO – Exposure to fresh red cells may be associated with immune suppression because viable white cells may also be present in the product...
From the Journals
Emicizumab effective in children with hemophilia A and inhibitors
Emicizumab stands to become the “next-generation standard of care” for these pediatric patients, report says.